DALLAS, TX -- August 13, 2026 --Burcon Nutrascience Corporation (TSX: BU): Stonegate Capital Partners updates their coverage on Burcon Nutrascience Corporation (TSX: BU). Burcon’s 1Q27 results reinforce the transition from technology validation to commercial execution. Revenue increased 54% q/q and 273% y/y to $1.28M, active buying customers reached 40 from 30+ previously, and repeat purchasing continues to build. Importantly, the $1.76M inventory write-down masked a much narrower underlying gross loss. The focus is now on whether improving customer traction can support the sizable 2H revenue ramp required to reach the prior CY26 sales objective while Burcon expands Galesburg capacity and moves toward positive cash flow.
Product Pipeline: Customer activity continues to broaden across powdered beverages, nutrition bars, snacks, plant-based foods, and other applications, spanning smaller and midsized brands alongside a couple of anchor customers providing base facility volume. Sales now extend across the full portfolio, and management said sunflower protein launched ahead of the prior 2027 commercialization timeline. Repeat purchasing is the more important development, as customers move from initial orders toward higher frequency and larger volumes, improving recurring-revenue visibility as new customers enter the funnel. Management remains focused on North America and views higher-protein consumption, including GLP-1-related nutrition needs, as a multi-year demand driver.
Financing Makes Room for Growth: Burcon launched an up-to-$8.1M convertible debenture financing with significant insider participation expected. The unsecured debentures carry a 15% coupon, mature in 48 months, and convert at $1.60 per share, with closing expected following shareholder approval, subject to TSX approval and other conditions. The Company also drew a $1.4M related-party bridge loan and retains $3.0M of undrawn capacity under its senior secured facility. Proceeds are intended for inventory, labor, production efficiency, capacity expansion, working capital, and debt reduction. The additional liquidity should support Galesburg expansion and plant efficiency, with revenue scaling and progress toward cash-flow breakeven important before additional outside capital is required. ProMan is also evaluating facility investment, while licensing remains part of the longer-term scaling framework.
Financial Overview: Revenue of $1.28M included $0.96M of protein sales and $0.32M of contract manufacturing revenue and was below the $1.90M S&P consensus. Cost of sales was $3.40M, including a $1.76M inventory write-down; excluding that item, underlying gross loss narrowed to approximately $0.37M versus the reported $2.12M, suggesting Galesburg economics are improving as production scales. Underlying gross margin remained negative, leaving utilization and fixed-cost absorption as the key margin variables. Net loss was $3.78M, operating cash use was $2.38M, and quarter-end cash was $0.87M with negative working capital of $11.2M. Management reiterated an expectation for double-digit CY26 revenue and a crossover to positive cash flow during the calendar year; the prior $10M sales objective implies roughly $7.9M of 2H sales.
Valuation: We use a DCF Model to frame our valuation of BU. Our DCF analysis relies on a range of discount rates between 13.75% and 16.25%, which arrives at a valuation range of $7.85 to $11.52 with a price target of $9.38.
